首页> 外文OA文献 >Influence of microencapsulated probiotic intake on myeloperoxidase activity in TNBS-induced colitis in rats
【2h】

Influence of microencapsulated probiotic intake on myeloperoxidase activity in TNBS-induced colitis in rats

机译:微囊化益生菌摄入对大鼠TNBs诱导的结肠炎中髓过氧化物酶活性的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The hypothesis that the intestinal bacterial flora contributes to the pathogenesis of inflammatory bowel disease (IBD) has been supported by experimental and clinical evidence. The dysbiosis present in this condition is related to dysregulation of mucosal immune response. One of the indicators of leukocyte infiltration at the sites of inflammation is the activity of myeloperoxidase (MPO). Numerous studies have been conducted in order to examine the effects of probiotic intake in IBD. However, during ingestion of probiotics, the harsh conditions which are present in the gastrointestinal (GI) tract often impair the delivery of viable microorganisms in the lower intestine. For this reason, probiotic (Lactobacillus casei 01) was incorporated in Ca-alginate-microparticles coated with whey protein and the effects of the formulation were examined in rat model of TNBS (trinitrobenzene sulfonic acid) - derived colitis.udThe objective of this work was to examine the lower intestine MPO activity after induction of TNBS colitis in rats, and to compare the effects of ingestion of microparticulate probiotic formulation vs non-encapsulated probiotic.udThe effect on MPO activity was assessed after oral administration of the microparticulate L. casei formulation (once daily during 21 days; probiotic viability 8,7 log10cfu/g) to Wistar rats in which inflammation was induced by intrarectal administration of TNBS (10 mg in 0.25 ml 50% ethanol). For comparison, a group of Wistar rats received the same amount of non-encapsulated L.casei (8,7 log10cfu/g). At the same time, a negative and a positive (TNBS) control group were also tested. The MPO activity was measured as described by Peran et al., 2007.udThe obtained values of MPO confirmed the presence of inflammation in our rat model, with the highest activity noted in the positive (TNBS) control group. The activity of MPO was found to be lower in the group of rats that were administered a microparticulate probiotic formulation, in comparison to the group that was administered non-encapsulated probiotic. These results suggest that encapsulation of L. casei efficiently protects the probiotic during the GI transit, therefore resulting in better colonization of the lower intestine, which subsequently results in lower MPO activity. Still, other indicators of gut wall immune response should be examined in order to confirm and support the current finding that microencapsulated probiotic confer better effects than non-encapsulated one.ud
机译:实验和临床证据支持了肠道细菌菌群促成炎症性肠病(IBD)发病机理的假说。在这种情况下存在的营养不良与粘膜免疫反应失调有关。炎症部位白细胞浸润的指标之一是髓过氧化物酶(MPO)的活性。为了检查益生菌在IBD中的摄入量,已经进行了大量研究。然而,在摄取益生菌的过程中,胃肠道(GI)中存在的恶劣条件通常会损害下层小肠中存活微生物的传递。因此,将益生菌(干酪乳杆菌01)掺入涂有乳清蛋白的海藻酸钙微粒中,并在TNBS(三硝基苯磺酸)大鼠结肠炎模型中检查了制剂的作用。 ud这项工作的目的旨在检查大鼠TNBS结肠炎后肠道MPO活性的降低,并比较摄入微粉益生菌制剂和未包囊的益生菌的效果。 ud对口服L. casei微粒对MPO活性的影响进行评估配方(21天每天一次;益生菌生存力8,7 log10cfu / g)给Wistar大鼠,其中通过直肠内施用TNBS(10 mg在0.25 ml 50%乙醇中)诱导炎症。为了比较,一组Wistar大鼠接受相同量的未包囊的干酪乳杆菌(8,7 log10cfu / g)。同时,还测试了阴性和阳性(TNBS)对照组。按照Peran等人(2007)的方法测量MPO活性。获得的MPO值证实了我们的大鼠模型中存在炎症,阳性(TNBS)对照组的活性最高。与给予非胶囊化益生菌的组相比,在给予微粒益生菌制剂的组中,MPO的活性较低。这些结果表明,干酪乳杆菌的封装有效地保护了胃肠道运输过程中的益生菌,因此导致了下肠道的更好定殖,随后导致了更低的MPO活性。仍然,应检查肠壁免疫反应的其他指标,以证实和支持当前的发现,即微囊化益生菌比未囊化的益生菌具有更好的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号